Safety of biologics therapy : monoclonal antibodies, cytokines, fusion proteins, hormones, enzymes, coagulation proteins, vaccines, botulinum toxins /: monoclonal antibodies, cytokines, fusion proteins, hormones, enzymes, coagulation proteins, vaccines, botulinum toxins. (2016)

• Record Type: Book
• Further Information: Note: Brian A. Baldo.
• Authors: Baldo, B. A
• Contents: Dedication; Preface; Contents; Chapter 1: Approved Biologics Used for Therapy and Their Adverse Effects; Biologics; US Guidelines; European Guidelines; Biologics and Small Molecule Drugs; Protein Therapeutics; Some Complexities of Protein Therapeutics: Perceived Advantages and Some Problems; The Evolving Biologics Market; Adverse Drug Reactions; Definitions; Terminology: Adverse Reactions and Adverse Events; Classification of Adverse Drug Reactions; Hypersensitivities; Other Adverse Drug Reaction Categories; Syndromes That May Be Associated with Biologic Therapies Capillary Leak Syndrome Cytokine Release Syndrome; Hemophagocytic Lymphohistiocytosis; Macrophage Activation Syndrome; Systemic Inflammatory Response Syndrome; Tumor Lysis Syndrome; Posterior Reversible Encephalopathy Syndrome; Immune Reconstitution Inflammatory Syndrome; Progressive Multifocal Leukoencephalopathy; Summary; Further Reading; Chapter 2: Monoclonal Antibodies: Introduction; Monoclonal Antibodies for Therapy; Evolution of Therapeutic Monoclonal Antibodies: From Mouse to Man; Technological Advances in the Production of Monoclonal Antibodies Hybridoma Technology and Immortalization of Human B Cells Phage Display; Transgenic (Knockout) Mice; Monoclonal Antibodies from Single Human B Cells by Gene Cloning; IgG Antibody Subclasses; Glycosylation of Monoclonal Antibodies; Antibody-Dependent Cell-Mediated and Complement-­Dependent Cytotoxicities; Nomenclature for Monoclonal Antibodies; Breakdown of Antibody Type and Approved Indications for the Currently Approved Monoclonal Antibodies; Antibody-Drug Conjugates; Future Prospects of Monoclonal Antibody Therapy; Summary; Further Reading Chapter 3: Monoclonal Antibodies Approved for Cancer Therapy Approved Monoclonal Antibodies for Cancer Therapy; Catumaxomab; Blinatumomab; Monoclonal Antibodies Targeting CD20: Rituximab, Ibritumomab, Ofatumumab, and Obinutuzumab; Rituximab; Ibritumomab Tiuxetan; Ofatumumab; Obinutuzumab; Brentuximab Vedotin; Alemtuzumab; Monoclonal Antibodies Targeting Epidermal Growth Factor Receptor: Cetuximab, Panitumumab, and Necitumumab; Resistance to EGFR-Targeted Monoclonal Antibodies; Cetuximab; Panitumumab; Necitumumab; Bevacizumab; Ramucirumab Monoclonal Antibodies Targeting Human Epidermal Growth Factor 2 (HER2): Pertuzumab, Trastuzumab, and Ado-­trastuzumab Emtansine Pertuzumab; Trastuzumab; Ado-trastuzumab Emtansine; Denosumab; Ipilimumab; Siltuximab; Monoclonal Antibodies Targeting Programmed Cell Death Protein 1 (PD-1): Pembrolizumab and Nivolumab; Checkpoint Inhibitors and PD-1; Targeting PD-1 in Cancer Therapy; Pembrolizumab; Nivolumab; Dinutuximab; Daratumumab; Elotuzumab; Recent Approval: Atezolizumab; Range of Side Effects of Monoclonal Antibodies Used for Cancer Therapy
• Publisher Details: Switzerland : Springer
• Publication Date: 2016
• Extent: 1 online resource (xxi, 610 pages), illustrations (some color)
• Subjects: 615.3; Biologicals -- Side effects; MEDICAL / Pharmacology; Biologicals -- Side effects; Biological Products -- adverse effects; Electronic books; Electronic books
• Languages: English
• ISBNs: 9783319304724; 3319304720
• Related ISBNs: 9783319304700; 3319304704
• Notes: Note: Includes bibliographical references and index.; Note: Online resource; title from PDF title page (SpringerLink, viewed August 23, 2016).
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.